Nisoli E, Carruba M O
Center for Study and Research on Obesity, University of Milan, Department of Preclinical Sciences, L. Sacco Hospital, Milan, Italy.
J Endocrinol Invest. 2002 Nov;25(10):905-14. doi: 10.1007/BF03344055.
Obesity is a multi-factorial, chronic disorder that has reached epidemic proportions in most industrialized countries and is threatening to become a global epidemic. Obese patients are at a higher risk from coronary artery disease, hypertension, hyperlipidemia, diabetes mellitus, certain cancers, cerebrovascular accidents, osteoarthritis, restrictive pulmonary disease, and sleep apnea. Obesity is a particularly challenging clinical condition to treat, because of its complex pathophysiological basis. Indeed, body weight represents the integration of many biological and environmental components. Efforts to develop innovative anti-obesity drugs have been recently intensified. In broad terms, researchers use different distinct strategies: first, to reduce energy intake; second, to increase energy expenditure; third, to alter the partitioning of nutrients between fat and lean tissue. In the present review we concentrate on the first of these strategies, by underlining the new pharmacological tools which are presently studied.
肥胖是一种多因素的慢性疾病,在大多数工业化国家已达到流行程度,并有可能成为全球性流行病。肥胖患者患冠状动脉疾病、高血压、高脂血症、糖尿病、某些癌症、脑血管意外、骨关节炎、限制性肺病和睡眠呼吸暂停的风险更高。由于其复杂的病理生理基础,肥胖是一种特别具有挑战性的临床病症。事实上,体重代表了许多生物和环境因素的综合。最近,开发创新抗肥胖药物的努力有所加强。广义而言,研究人员采用不同的独特策略:第一,减少能量摄入;第二,增加能量消耗;第三,改变脂肪组织和瘦组织之间营养物质的分配。在本综述中,我们着重探讨这些策略中的第一种,强调目前正在研究的新的药理学工具。